Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Markers of Bone Metastases in Breast and Lung Cancers

  • Published : 2012.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Aim and Background: The aim of the present study was to evaluate correlations between serum osteocalcin, osteoprotegerin and NTX (Cross-linked N-telopeptides of Type I Collagen) and urinary NTX in breast and lung cancer patients with bone metastases. These four markers are considered to have important roles in bone formation, resorption and metastases. Methods: Four markers were determined in the sera of 60 breast cancer and 21 lung cancer patients and healthy controls (n=30). Serum levels were studied using ELISA and EIA. Results: The median levels of serum osteoprotegerin (p<0.001) and osteocalcin (p=0.003) were higher in patients. Significant correlations were observed between the serum NTX-osteocalcin (r=0.431; p<0.001), serum NTX-osteoprotegerin (r=0.42; p=0.003) and serum NTX - urine NTX (r=0.255; p=0.022). Conclusion: We conclude that osteocalcin, osteoprotegerin and NTX are independent diagnostic tools. Due to the ease of urine collection, urine NTX may be applied routinely to allow early detection of bone metastases and indicate progression of the disease.

Keywords

References

  1. Bossuyt PM, Reitsma JB, Bruns DE et al., STARD Group (2004). Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Fam Pract, 21, 4-10. https://doi.org/10.1093/fampra/cmh103
  2. Calvo MS, Eyre DR, Gundberg CM (1996). Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev, 17, 333-68.
  3. Chung JH, Park MS, Kim YSet al. (2005). Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer. Yonsei Med J, 46, 388-93. https://doi.org/10.3349/ymj.2005.46.3.388
  4. Demers LM, Costa L, Chinchilli VM et al. (1995). Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem, 41, 1489-94.
  5. Joerger M, Huober J (2012). Diagnostic and prognostic use of bone turnover markers. Recent Results Cancer Res, 192, 197-223. https://doi.org/10.1007/978-3-642-21892-7_10
  6. Johansen JS, Brasso K, Iversen P et al. (2007). Changes of biochemical markers of bone turnover and YKL-40 following hormonaltreatment for metastatic prostate cancer are related to survival. Clin Cancer Res, 13, 3244-9. https://doi.org/10.1158/1078-0432.CCR-06-2616
  7. Jung K, Miller K, Wirth M et al. (2011). Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid. Eur Urol, 59, 604-12. https://doi.org/10.1016/j.eururo.2010.12.006
  8. Kamby C, Egsmose C, Soletormos G, Dombernowsky P (1993). The diagnostic and prognostic value of serum bone GLA protein (osteocalcin) in patients with recurrent breast cancer. Scand J Clin Lab Invest, 53, 439-46. https://doi.org/10.3109/00365519309092538
  9. Kamiya N, Suzuki H, Endo T et al. (2012). Clinical usefulness of bone markers in prostate cancer with bone metastasis. Int J Urol, 10, 1442-2042
  10. Lacey DL, Timms E, Tan HL et al. (1998). Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 93, 165-76. https://doi.org/10.1016/S0092-8674(00)81569-X
  11. Lee JS, Tung CH (2011). Osteocalcin biomimic recognizes bone hydroxyapatite. Chembiochem, 12, 1669-73. https://doi.org/10.1002/cbic.201100162
  12. Lipton A, Costa L, Coleman RE (2011). Bone turnover markers: tools for prognosis and monitoring response to bisphosphonates? Breast Dis, 33, 59-69.
  13. Meier C, Kraenzlin ME (2012). Osteoporosis: evaluation, diagnosis and monitoring. Ther Umsch, 69, 145-52. https://doi.org/10.1024/0040-5930/a000267
  14. Roodman GD (2012). Genes associate with abnormal bone cell activity in bone metastasis. Cancer Metastasis Rev, 10, 10555-1112.
  15. Salem AM, Zohny SF, Abd El-Wahab MM, Hamdy R (2007). Predictive value of osteocalcin and beta-CrossLaps in metastatic breast cancer. Clin Biochem, 40, 1201-8. https://doi.org/10.1016/j.clinbiochem.2007.07.006
  16. Simonet WS, Lacey DL, Dunstan CR, et al (1997). Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 89, 309-19. https://doi.org/10.1016/S0092-8674(00)80209-3
  17. Tamiya M, Suzuki H, Kobayashi M et al. (2011). Usefulness of the serum cross-linked N-telopeptide of type I collagen as a marker of bone metastasis from lung cancer. Med Oncol, 29, 215-8.
  18. Yasuda H, Shima N, Nakagawa N et al. (1998). Osteoclast differentiation factor is a ligand for osteoprotegerin / osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA, 95, 3597-602. https://doi.org/10.1073/pnas.95.7.3597

Cited by

  1. Temporal Trends in the Inflammatory Cytokine Profile of Human Breastmilk vol.9, pp.10, 2014, https://doi.org/10.1089/bfm.2014.0043
  2. Osteoprotegerin: A novel biomarker for inflammatory bowel disease and gastrointestinal carcinoma vol.31, pp.8, 2016, https://doi.org/10.1111/jgh.13324